Edgar Filing: INTERNATIONAL ISOTOPES INC

International Isotopes Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2008

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _______________

Commission file number:

0-22923

INTERNATIONAL ISOTOPES INC.

(Exact name of registrant as specified in its charter)


Texas		74-2763837
(State of incorporation)		(IRS Employer Identification Number)

4137 Commerce Circle

Idaho Falls, Idaho, 83401

(Address of principal executive offices)

(208) 524-5300

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

ý Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer," "accelerated filer” and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨

Accelerated Filer ¨

Non-accelerated filer ¨ (Do not check if smaller reporting company)

Smaller Reporting Company ý

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

¨ Yes ý No

As of August 14, 2008 the number of shares of Common Stock, $.01 par value, outstanding was 280,403,608.

INTERNATIONAL ISOTOPES INC.

TABLE OF CONTENTS


	PAGE
PART 1 – FINANCIAL INFORMATION
Item 1 – Financial Statements
Unaudited Condensed Consolidated Balance Sheets at June 30, 2008 and December 31, 2007	3
Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2008 and 2007	4
Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2008 and 2007	5
Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2 – Management's Discussion and Analysis of Operations or Plan of Operation	12
Item 3 – Quantitative and Qualitative Disclosures About Market Risk	14
Item 4 – Disclosure, Controls, and Procedures	14

PART II – OTHER INFORMATION
Item 6 – Exhibits	15

Signatures	15

Part I. Financial Statements

Item 1. Financial Statements

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Balance Sheets


Assets	June 30, 2008		December 31, 2007
Current assets
Cash and cash equivalents	$	1,172,030	$	121,887
Accounts receivable		564,763		518,464
Inventories		2,505,487		2,502,266
Prepaids and other current assets		60,393		94,936
Total current assets		4,302,673		3,237,553

Long-term assets
Restricted certificate of deposit		258,000		184,937
Property, plant and equipment, net		3,020,306		2,095,610
Capitalized lease disposal costs, net		94,390		83,271
Investment		1,290,000		330,000
Patents, net		99,315		91,857
Total long-term assets		4,762,011		2,785,675
Total assets	$	9,064,684	$	6,023,228


Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	261,983	$	441,910
Accrued liabilities		390,542		402,950
Current installments of capital leases		31,349		29,648
Current installments of notes payable		1,448,528		937,969
Total current liabilites		2,132,402		1,812,477

Long-term liabilities
Obligation for lease disposal costs		253,801		221,742
Capital leases, excluding current installments		64,027		80,138
Notes payable, excluding current installments		112,121		669,859
Mandatorily redeemable convertible preferred stock		850,000		850,000
Total long-term liabilities		1,279,949		1,821,739
Total liabilities		3,412,351		3,634,216

Stockholders' Equity
Common stock, $0.01 par value; 500,000,000 shares authorized; 280,395,304 and 250,481,324 shares issued and outstanding respectively		2,803,953		2,504,811
Additional paid-in capital		96,113,740		92,436,907
Accumulated deficit		(93,265,360)		(92,552,706)
Total stockholders' equity		5,652,333		2,389,012
Total liabilities and stockholders' equity	$	9,064,684	$	6,023,228

See accompanying notes to condensed consolidated financial statements.

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Operations


	Three Months ended June 30,				Six Months ended June30,
	2008		2007		2008		2007
Sale of product	$	1,876,042	$	1,203,305	$	3,183,980	$	2,105,937
Cost of product		925,371		647,888		1,534,907		1,176,907
Gross profit		950,671		555,417		1,649,073		929,030

Operating costs and expenses:
Salaries and contract labor		507,865		358,560		1,020,477		694,822
General, administrative and consulting		663,415		496,491		1,280,582		1,072,196
Research and development		6,390		10,061		22,118		18,919
Total operating expenses		1,177,670		865,112		2,323,177		1,785,937

Operating loss		(226,999)		(309,695)		(674,104)		(856,907)

Other income (expense):
Other income		8,386		-		20,402		68,870
Interest income		8,042		2,082		13,356		4,018
Interest expense		(36,139)		(43,835)		(72,308)		(85,975)
Total other expense		(19,711)		(41,753)		(38,550)		(13,087)
Net loss	$	(246,710)	$	(351,448)	$	(712,654)	$	(869,994)

Net loss per common share – basic and diluted	$	(0.00)	$	(0.00)	$	(0.00)	$	(0.00)

Weighted average common shares outstanding – basic and diluted		277,122,436		238,935,747		270,055,656		229,244,222

See accompanying notes to condensed consolidated financial statements.

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Cash Flows


	Six Months ended June 30,
	2008		2007
Cash flows from operating activities:
Net loss	$	(712,654)	$	(869,994)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		193,390		165,767
Accretion of obligation for lease disposal costs		13,524		7,645
Compensation expense related to issuance of options		179,585		88,467
Changes in operating assets and liabilities:
Accounts receivable		(46,299)		(308,932)
Prepaids and other assets		34,543		57,329
Inventories		(3,221)		(161,894)
Accounts payable and accrued liabilities		(192,333)		165,123
Net cash used in operating activities		(533,465)		(856,489)

Cash flows from investing activities:
Restricted certificate of deposit		(73,063)		(3,952)
Purchase of RadQual interest		-		(275,000)
Purchase of property, plant and equipment		(1,118,130)		(228,534)
Net cash used in investing activites		(1,191,193)		(507,486)

Cash flows from financing activities:
Proceeds from exercise of warrants		2,799,997		269,539
Proceeds from sale of stock		36,393		1,203,800
Principal payments on notes payable and capital leases		(61,589)		(154,887)
Net cash provided by financing activities		2,774,801		1,318,452

Net decrease in cash and cash equivalents		1,050,143		(45,523)
Cash and cash equivalents at beginning of period		121,887		169,702
Cash and cash equivalents at end of period	$	1,172,030	$	124,179

Supplemental disclosure of cash flow activities:
Cash paid for interest	$	102,535	$	115,758

Supplemental disclosure of noncash transactions:
Conversion of note payable and accrued interest into common stock	$	-	$	673,614
Issuance of note payable for property and equipment	$	-	$	42,499
Issuance of 392,620 shares of common stock at $0.14 per share to acquire investment	$	-	$	55,000
Increase in Lease Disposal Costs	$	18,535	$	-
Acquisition of interest in RadQual LLC in exchange for issuance of 1,370,753 shares of stock.	$	960,000	$	-

See accompanying notes to condensed consolidated financial statements.

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements

(1)

The Company and Basis of Presentation

International Isotopes Inc. (the Company) was incorporated in Texas in November 1995. The consolidated financial statements include all the accounts of the Company and its wholly owned subsidiaries, International Isotopes Idaho Inc., International Isotopes Fluorine Products Inc., and International Isotopes Transportation Services Inc., all of which are Idaho corporations. The Company’s headquarters and all operations are located in Idaho Falls, Idaho.

Nature of Operations –The Company’s business consists of six major business segments which include: Nuclear Medicine, Cobalt Products, Radiochemical Products, Fluorine Products, Radiological Services, and Transportation.

With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be three years. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets.

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries International Isotopes Idaho Inc., International Isotopes Fluorine Products Inc., and International Isotopes Transportation Services Inc. All significant intercompany accounts and transactions have been eliminated in consolidation.

Interim Financial Information – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the three and six-month periods ending June 30, 2008, are not necessarily indicative of the results that may be expected for the year ending December 31, 2008. The accompanying financial statements should be read in conjunction with the Company’s most recent audited financial statements.

Recent Accounting Standards - In September 2006, the Financial Accounting Standards Board (FASB) issued SFAS No. 157, Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. In February 2008, the FASB issued FASB Staff Position (FSP FIN) No. 157-2 which extended the effective date for certain nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008. The adoption of the portions of SFAS No. 157 that were not postponed by (FSP FIN) No. 157-2 did not have a material impact on our consolidated financial statements. The Company does not expect the adoption of the postponed portions of SFAS No. 157 to have a material impact on our consolidated financial statements.

(2)

Current Developments and Liquidity

Business Condition – Since inception, the Company has suffered substantial losses. During the six-month period ended June 30, 2008, the Company had a loss of $712,654 and operations used cash of $533,465. During the same period in 2007, the Company had a loss of $869,994 and operations used cash of $856,489. During the three-month period ended June 30, 2008, the Company had a loss of $246,710 as compared to a loss of $351,448 for the similar period in 2007. The Company believes that continued growth in their major business segments, and the start of the fluorine product sales will lead to increased revenue and improved cash flow for the Company. Based upon these improvements to business conditions, management expects to generate sufficient cash flows to meet operational needs during 2008; however, there is no assurance that these cash flows will occur.

(3)

Net Loss Per Common Share - Basic and Diluted

At June 30, 2008, and 2007, the Company had the following common stock equivalents outstanding that were not included in the computation of diluted net loss per common share as their effect would have been anti-dilutive, thereby decreasing the net loss per common share:


	June 30,
	2008	2007
Stock options	18,780,000	22,650,000
Series B warrants	-	4,061,058
Class C warrants	-	13,333,331
Class D warrants	-	13,333,331
Class E warrants	13,333,331	-
850 shares of Series B redeemable
convertible preferred stock	425,000	425,000
	32,538,331	53,802,720

(4)

Inventories

Inventories consist of the following at June 30, 2008 and December 31, 2007:


	June 30, 2008		December 31, 2007
Raw materials	$	254,343	$	260,611
Work in progress		2,251,144		2,241,655
	$	2,505,487	$	2,502,266

(5)

Asset Acquisition

In May 2008, the Company entered into an Asset Purchase Agreement with Sequoyah Fuels Corporation to which the Company purchased certain tangible and intangible assets related to Sequoyah’s depleted uranium hexafluoride to depleted uranium tetrafluoride conversion facility located in Gore, Oklahoma. On May 30, 2008, the Company and Sequoyah entered into a Technical Support Services Agreement pursuant to which Sequoyah will perform up to 500 hours of certain technical services to support the Acquired Assets. As consideration for the acquired assets and the service agreement, the Company paid Sequoyah $900,000 cash. The Company is currently considering how to allocate the purchase price among tangible assets, intangible assets and the service agreement and currently has the entire $900,000 recorded as production equipment. These assets are not being depreciated until such time as the assets are placed into service.

(6)

Stockholders’ Equity and Warrants

Options

During the six months ended June 30, 2008, certain option holders exercised 470,000 options under cashless exercises and the Company issued 366,568 shares of common stock. Certain option holders also exercised 1,500,000 options at $0.20 per share for $30,000 and the Company issued 1,500,000 shares of common stock.

Warrants

During January 2008, 13,333,331 Series D warrants were exercised for cash totaling $1,466,666. In April 2008, the holders of all Class C warrants agreed to amend the terms of the Class C warrant to allow for the Company’s call of those warrants. Subsequent to completing this modification, all Class C warrants were exercised for cash totaling $1,333,333 and the Company issued 13,333,331 exchange (Class E) warrants in accordance with the terms of the Class C warrant. Class E warrants entitle the holder to purchase shares of common stock, $0.01 par value per share, at an exercise price equal to $0.869 per share. Class E warrants expire March 20, 2011.

Employee Stock Purchase

During the six months ended June 30, 2008, the Company issued 9,998 shares of common stock to employees for proceeds of $6,393. All of these shares were issued in accordance with the Company’s employee stock purchase plan.

Stock-based Compensation Plans

The Company accounts for issuances of stock-based compensation to employees under the provisions of Statement of Financial Accounting Standards (SFAS) No. 123(R). SFAS 123R requires the recognition of the cost of employee services received in exchange for an award of equity instruments in the financial statements and is measured based on the grant date fair value of the award. SFAS 123R also requires the stock option compensation expense to be recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

The Company accounts for its issuances of stock-based compensation to non-employees for services using the measurement date guidelines enumerated in SFAS 123(R) and EITF 96-18. Accordingly, the value of any awards that were vested and non forfeitable at their date of issuance were measured based on the fair value of the equity instruments at the date of issuance. The non-vested portion of awards that are subject to the future performance of the counterparty are adjusted at each reporting date to their fair values based upon the then current market value of the Company’s stock and other assumptions that management believes are reasonable. The fair value of the stock options granted was calculated using the Black-Scholes option pricing model.

In January 2008, the Company granted stock options to a consultant to purchase 400,000 shares of common stock, with an exercise price of $0.77 per share. The options vest at the rate of 25% each year over four years beginning one year from the date granted. The options had a grant date fair value of $258,012 or $0.65 per share as calculated using the Black-Scholes option pricing model.

The weighted average assumptions for options granted during the six months ended June 30, 2008 used an expected dividend yield of zero and a risk-free interest rate of 3.33%. The expected volatility factor used was 110.92% with an expected life of 6.26 years. Weighted average fair value per share was assumed to be $0.62.

In accordance with EITF 96-18, as of June 30, 2008, the options awarded to consultants were re-valued using the Black-Scholes option pricing model and had a fair value of $227,130 or $0.57 per share with the following assumptions: volatility of 89.28%, remaining expected life of six years, risk free interest rate of 3.48% and no dividends.

The expected life of stock options represents the period of time that the stock options granted are expected to be outstanding based on historical exercise trends. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury bill rate for the expected life of the related stock options. The dividend yield represents the anticipated cash dividend over the expected life of the stock options.

Compensation expense charged against income for stock based awards during the six months ended June 30, 2008 was $179,588, as compared to $88,467 for the six months ended June 30, 2007, and is included in general and administrative expense in the accompanying financial statements.

A summary of the status of the stock options as of June 30, 2008, and changes during the six months ended June 30, 2008, is as follows:


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
Fixed Options	Shares	Exercise Price		Term	Value
Outstanding at December 31, 2007	21,350,000	$	0.05
Granted	400,000		0.77
Exercised	(1,970,000)		0.07		$	1,521,500
Forfeited	(1,000,000)		0.17
Outstanding at June 30, 2008	18,780,000		0.09	5.2	$	13,324,600

Exercisable at June 30, 2008	15,455,000		0.04	4.5	$	11,707,600

The intrinsic value of outstanding and exercisable shares is based on a June 30, 2008 closing price of the Company’s common stock of $0.80 per share.

As of June 30, 2008, there was approximately $438,098 of unrecognized compensation cost related to stock options that will be recognized over a weighted average period of 2.1 years.

(7)

Acquisition of Interest in RadQual, LLC

During April 2007, the Company acquired 6% of the equity interests of RadQual, LLC for a cash payment of $330,000. In May 2008, the Company acquired an additional 18.5% interest by issuing 1,370,753 shares of common stock valued at $960,000 or $0.70 per share. The remaining 75.5% ownership of RadQual is concentrated among a very small group of investors and due to this concentration the Company is unable to influence significant control. The company did not receive financial information in a manner timely enough to convert to the equity method of accounting for this asset; accordingly, the investment in RadQual will continue to be recorded at the lower of cost or fair value in accordance with FASB Interpretation 35 “Criteria for Applying the Equity Method of Accounting for Investments in Common Stock.” The 24.5% ownership of RadQual has been recorded at cost of $1,290,000.

(8)

Commitments and Contingencies

Dependence on Third Parties

The production of HSA Cobalt is dependent upon the U.S. Department of Energy, and its prime operating contractor, which controls the reactor operations and, therefore, controls the continued production of cobalt in the government funded reactor. The revenue associated with the sale of HSA Cobalt is largely dependent on General Electric, the Company’s sole customer for this product. Nuclear Medicine Reference and Calibration Standard manufacturing is conducted under an exclusive contract with another of our customers, RadQual, LLC, which in turn has an agreement in place with several companies for distributing the product. A loss of either of these customers could adversely affect operating results by causing a delay in production or a possible loss of sales.

Contingencies

Because all of the Company’s business segments involve radioactive materials the Company is required to have an operating license from the Nuclear Regulatory Commission (“NRC”) and specially trained staff to handle these materials. The Company has an NRC operating license and has amended this license several times to increase the amount of material permitted within the facility. Additional processing capabilities and license amendments could be implemented that would permit processing of other reactor produced radioisotopes by the Company but this license does not currently restrict the volume of business operation performed or projected to be performed in the coming year. An irrevocable, automatic renewable letter of credit against a Certificate of Deposit at Texas State Bank and Wells Fargo Bank has been used to provide the financial assurance required by the NRC for the Idaho facility license.

(9)

Segment Information

Segment information has been prepared in accordance with SFAS No. 131, “Disclosure About Segments of an Enterprise and Related Information.”

The Company has six reportable segments which include; Nuclear Medicine, Cobalt Products, Radiochemical Products, Fluorine Products, Radiological Services, and Transportation. Information regarding the operations and assets of these reportable business segments is contained in the following table:


	Three Months ended June 30,				Six Months ended June 30,
Sale of Product	2008		2007		2008		2007

Radiochemical Products	$	349,990	$	284,092	$	668,398	$	510,006
Cobalt Products		879,516		175,015		1,150,044		214,040
Nuclear Medicine Standards		464,288		455,910		911,698		919,778
Radiological Services		166,548		219,290		412,270		366,899
Fluorine Products		-		-		-		-
Transportation		15,700		68,998		41,570		95,214
Total Segments		1,876,042		1,203,305		3,183,980		2,105,937
Corporate revenue		-		-		-		-
Total Consolidated	$	1,876,042	$	1,203,305	$	3,183,980	$	2,105,937


	Three Months ended June 30,				Six Months ended June 30,
Depreciation and Amortization	2008		2007		2008		2007

Radiochemical Products	$	11,326	$	11,326	$	22,652	$	22,721
Cobalt Products		26,181		15,906		48,500		31,812
Nuclear Medicine Standards		846		1,147		1,692		2,905
Radiological Services		1,991		144		2,804		458
Fluorine Products		50,917		38,258		91,763		77,789
Transportation		4,666		4,574		9,257		5,847
Total Segments		95,927		71,355		176,668		141,532
Corporate depreciation and amortization		3,918		13,254		16,722		24,235
Total Consolidated	$	99,845	$	84,609	$	193,390	$	165,767


	Three Months ended June 30,				Six Months ended June 30,
Segment Income (Loss)	2008		2007		2008		2007

Radiochemical Products	$	52,218	$	39,425	$	58,550	$	58,308
Cobalt Products		440,240		23,324		635,514		30,411
Nuclear Medicine Standards		219,897		194,202		393,867		337,221
Radiological Services		101,938		140,721		275,694		216,521
Fluorine Products		(310,003)		(223,137)		(598,358)		(491,914)
Transportation		(48,328)		3,189		(83,287)		(21,856)
Total Segments		455,962		177,724		681,980		128,691
Corporate Loss		(702,672)		(529,172)		(1,394,634)		(998,685)
Net Loss	$	(246,710)	$	(351,448)	$	(712,654)	$	(869,994)


	Three Months ended June 30,				Six Months ended June 30,
Expenditures for Segment Assets	2008		2007		2008		2007

Radiochemical Products	$	-	$	-	$	-	$	-
Cobalt Products		23,771		83,958		141,771		83,958
Nuclear Medicine Standards		-		-		-		-
Radiological Services		3,200		-		51,995		-
Fluorine Products		912,836		101,099		914,473		128,911
Transportation		6,633		9,940		6,633		52,439
Total Segments		946,440		194,997		1,114,872		265,308
Corporate purchases		-		4,536		3,258		5,725
Total Consolidated	$	946,440	$	199,533	$	1,118,130	$	271,033


	June 30,		December 31,
Segment Assets	2008		2007

Radiochemical Products	$	342,004	$	311,278
Cobalt Products		3,116,746		2,915,698
Nuclear Medicine Standards		474,522		439,875
Radiological Services		93,977		28,374
Fluorine Products		2,077,758		1,255,049
Transportation		57,142		59,766
Total Segments		6,162,149		5,010,040
Corporate assets		2,902,535		1,013,188
Total Consolidated	$	9,064,684	$	6,023,228

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF OPERATIONS

This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Quarterly Report are forward looking. In particular, statements regarding growth in our business segments; increased cash flow to meet operational needs; improvement in our financial strength, debt ratio and attractiveness to investors and lenders; future liquidity requirements; NRC licensing requirements; and the consequences of the loss of any of our major customers are forward looking. Forward-looking statements reflect management’s current expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Certain risks and uncertainties that could cause our actual results to differ significantly from management’s expectations are described in the risk factors set forth in our annual report on Form 10-KSB for the fiscal year ended December 31, 2007 filed with the securities and Exchange Commission on March 28, 2008. These factors, describe some but not all of the factors that could cause actual results to differ significantly from management’s expectations. The Company will not publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are urged, however, to review the factors set forth in reports that we file from time to time with the Securities and Exchange Commission.

RESULTS OF OPERATIONS

Three-month and six-month periods ended June 30, 2008, and 2007.

Revenues for the three and six-month period ended June 30, 2008 were $1,876,042 and $3,183,980 as compared to $1,203,305 and $2,105,937 for the same periods in 2007, an increase of $672,737 and $1,078,043 or approximately 56% and 51% respectively. The increase in total revenues was attributable to strong performance in cobalt products and radiochemical products business segments. Revenues from the sale of cobalt products for the six-month period ending June 30, 2008 were $1,150,044 compared to $214,040 for the similar period in 2007. Revenues from the sale of cobalt products for the three-month period ending June 30, 2008 were $879,516 compared to $175,015 for the similar period in 2007. This represents approximately a factor of five increase in revenue in the segment. The increase is largely attributable to continued increased sales of sealed cobalt sources and teletherapy capsules to numerous customers. The sales of bulk cobalt also had a significant impact upon revenues for the period. The timing of large bulk cobalt product sales during the course of the calendar year has a significant impact upon period comparisons.

Excluding bulk cobalt sales, revenues for the three-month period ended June 30, 2008, were $1,387,786 as compared to $1,203,305 for the same period in 2007, which represents an increase of $184,481 or 15%. Excluding bulk cobalt product sales, revenues for the six-month period ended June 30, 2008, were $2,695,724 as compared to $2,105,937 for the same period in 2007, which represents an increase of $589,787 or 28%. Management believes that excluding sales of bulk cobalt products from the period comparisons of revenues provides useful information to investors. Historically the Company has excluded all cobalt product sales for period comparisons. However, the growth in sales of cobalt products, such as sealed sources warrants adjusting this comparison to only exclude bulk cobalt product sales revenues for the period comparisons. Please refer to the following tables for a further analysis of this measure:

Three-Month Financial Measure Reconciliation


	Period ended June 30, 2008	Period ended June 30, 2007
Total Revenues	$1,876,042	$1,203,305
Bulk Cobalt Products Revenues	$488,256	$0
Total Revenues Excluding Cobalt Products Revenues	$1,387,786	$1,203,305

Six-Month Financial Measure Reconciliation


	Period ended June 30, 2008	Period ended June 30, 2007
Total Revenues	$3,183,980	$2,105,937
Bulk Cobalt Products Revenues	$488,256	$0
Total Revenues Excluding Cobalt Products Revenues	$2,695,724	$2,105,937

Revenues from the sale of radiochemical products for the three-month period ending June 30, 2008, were $349,990 compared to $284,092 for the similar period in 2007. Revenues from the sale of radiochemical products for the six-month period ending June 30, 2008, were $668,398 compared to $510,006 for the similar period in 2007. These represent increases in revenue of $65,898, or about 23%, and $158,392, or about 31% for the three and six-month periods respectively. Increases in the segment performance are attributable to increased sales of radiochemical iodine-131. Revenues from nuclear medicine products for the three-month period ending June 30, 2008 were $464,288 compared to $455,910 for the similar period in 2007. Revenues from the sale of nuclear medicine products for the six-month period ending June 30, 2008, were $911,698 compared to $919,778 for the similar period in 2007. This represents an increase in income of $8,378 or 1.1% and a decrease in income of $8,080 or less than 1% respectively. Revenues from radiological services segment for the three-month period ending June 30, 2008, were $166,548 compared to $219,290 for the similar period in 2007; a decrease of $52,742 or 24%. Revenues from radiological services segment for the six-month period ending June 30, 2008, were $412,270 compared to $366,899 for the similar period in 2007. This represents an increase in revenue of $45,371 or approximately a 12% increase and is primarily attributable to increased volumes of gemstone processing that have resulted following resolution of the regulatory issues that had limited revenues in this segment during 2007.

Gross profit for the three and six-month period ended June 30, 2008, was $950,671 and $1,649,073 compared to $555,417 and $929,030 for the same periods in 2007. These represent increases of $395,254 or 71%, and $720,043 or 78%, for the three and six month periods respectively. Operating expenses increased to $1,177,670 and $2,323,177 for the three and six-month period ended June 30, 2008, compared to $865,112 and $1,785,937 for the same periods of 2007. This represents an increase of $312,558 or 36%, and $537,240 or 30%, for the three and six-month periods respectively. However, overall operating costs declined from 85% and 72% of sales for the six and three-month periods in 2007, to 73% and 63% of sales for similar periods in 2008. Salaries and contract labor expenses for the three and six-month periods ended June 30, 2008 were $507,865 and $1,020,477 as compared to $358,560 and $694,822 for the same periods of 2007. General administrative expenses totaled $663,415 and $1,280,582 for the three and six-month periods ended June 30, 2008 as compared to $496,491 and $1,072,196 for the same periods of 2007. The increase in operating expense is attributed to the addition of full time staff, subcontractors, and legal counsel necessary to support continued growth of the fluorine products division including pilot plant demonstration and efforts related to equipment acquisition, raising capital, and protecting newly developed intellectual property. The Company also realized a significant increase in stock option expense.

Our net loss for the three and six-month periods ended June 30, 2008 was $246,710 and $712,654 compared to a loss of $351,448 and $869,994 for the same periods in 2007. The reduction in loss was attributable to savings in overall cost of goods sold and operational expense as they relate directly to sales.

Interest expense for the three and six-month period ended June 30, 2008, was $36,139 and $72,308 as compared to $43,835 and $85,975 for the same periods in 2007. The reduction in interest expense was attributable to a reduction in the principal balance owed.

LIQUIDITY AND CAPITAL RESOURCES

On June 30, 2008, we had cash and cash equivalents of $1,172,030. For the six-months ended June 30, 2008, net cash used in operating activities was $533,465. We used $1,191,193 for investing activities. Financing activities provided $2,774,801 from exercise of warrants and issuance and sale of Company stock.

At June 30, 2008, the Company had two outstanding loans with Texas State Bank. One loan carries an outstanding balance of $126,013 with an interest rate of 9.25% and matures September 15, 2011. The second loan has an outstanding balance of $567,246 with an interest rate of 10.25% , matures March 31, 2009, and is, therefore, reported as a current liability.

Our future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, and voluntary warrant redemption by shareholders. We have 13,333,331 Class E warrants still outstanding.

During January 2008, 13,333,331 Series D warrants were exercised for cash totaling $1,466,666. In April 2008, the holders of all Class C warrants agreed to amend the terms of the Class C warrant to allow for the Company’s call of those warrants. Subsequent to completing this modification, all Class C warrants were exercised for cash totaling $1,333,331 and the Company issued 13,333,331 exchange (Class E) warrants in accordance with the terms of the Class C warrant. Class E warrants entitle the holder to purchase shares of common stock, $0.01 par value per share, at an exercise price equal to $0.869 per share. Class E warrants expire March 20, 2011.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company has established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) to ensure that material information relating to the Company is made known to the officers who certify the Company’s financial reports and to other members of senior management and the Board of Directors. These disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that are filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's (“SEC”) rules and forms. Under the supervision and with the participation of management, including the principal executive officer and principal financial officer an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2008 was completed based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this evaluation, the principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures are functioning effectively.

Although our disclosure controls and internal controls were designed to provide reasonable assurance of achieving their objectives, and our principal executive officer and principal financial officer have determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There was no change in the Company’s internal control over financial reporting during the Company’s most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PARTII. OTHER INFORMATION

Item 6. Exhibits

3(i)

Second Amended and Restated Articles of Incorporation (incorporated by reference to Appendix C to the Company's definitive proxy statement on Schedule 14A filed on April 28, 2005).

3(ii)

Bylaws (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form SB-2 filed on May 1, 1997 (Registration No. 333-26269)).

4.1

Form of Class E Warrant (incorporated by reference to Exhibit 4.1 of the Company's Current Report of Form 8-K filed on April 21, 2008).

10.1

Letter Agreement effective as of April 9, 2008 (incorporated by reference to Exhibit 99.1 of the Company's Current Report of Form 8-K filed on April 21, 2008).

31.1

Certification under Section 302 of the Sarbanes-Oxley Act of 2002 for Chief Executive Officer.

31.2

Certification under Section 302 of the Sarbanes-Oxley Act of 2002 for Chief Financial Officer.

Certification by the Chief Executive and Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

In accordance with the requirements of the Exchange Act the registrant caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	International Isotopes Inc.
	(Registrant)


Date: August 14, 2008	By:	/s/ Steve T. Laflin
		Steve T. Laflin
		President and Chief Executive Officer

EXHIBIT INDEX

Exhibit

Number

Description of Document

3(i)

Second Amended and Restated Articles of Incorporation (incorporated by reference to Appendix C to the Company's definitive proxy statement on Schedule 14A filed on April 28, 2005).

3(ii)

Bylaws (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement on Form SB-2 filed on May 1, 1997 (Registration No. 333-26269)).

4.1

Form of Class E Warrant (incorporated by reference to Exhibit 4.1 of the Company's Current Report of Form 8-K filed on April 21, 2008).

10.1

Letter Agreement effective as of April 9, 2008 (incorporated by reference to Exhibit 99.1 of the Company's Current Report of Form 8-K filed on April 21, 2008).

31.1

Certification under Section 302 of the Sarbanes-Oxley Act of 2002 for Chief Executive Officer.

31.2

Certification under Section 302 of the Sarbanes-Oxley Act of 2002 for Chief Financial Officer.

Certification by the Chief Executive and Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.